For patients with non-muscle invasive bladder cancer, to bacillus Calmette-Guérin test may have a therapeutic effect, according to research published in the June issue of Journal of Urology.
Naoya Niva, a doctor from the Medical School of Keio University in Tokyo, and colleagues treated 498 patients with non-muscle invasive bladder cancer with adjuvant bacillus Calmette-Guérin; 320 patients were tested with the purified protein skin test for one or two weeks prior to therapy.
The researchers found that the median survival in average ± standard deviation was not less than 66.6 percent ± 2.8 and 59.1 ± 4.1 per cent for patients who do not pass and do not pass the test for the purified protein shell, respectively (P = 0.048). Between the groups was not significant difference in progression-free survival. Significant independent association with tumor relapse were observed throughout history of relapse of multiple tumors, strain Bacillus Calmette-Guérin Connaught, seven or more infiltrates Bacillus Calmette-Guérin and the purified protein subjected to skin test. Overall, 24.1 and 15.2 percent of patients who have passed and failed the test, respectively, have serious side effects associated with bacillus Calmette-Guérin (P = 0,02).
"Combination therapy with Bacillus Calmette-Guérin using test may improve oncologic outcomes of this therapy," the authors write.